

Dear

**FREEDOM OF INFORMATION – HAEMATOLOGICAL CANCER TREATMENT**

I write in response to your request for information in relation to treatment of haematological cancer in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis or regimen, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?: Daratumumab; Lenalidomide.

Answer:

<b>Patient treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
1.1 Daratumumab	111
1.2 Lenalidomide	206

Question:

2. How many patients with Multiple Myeloma were treated with the following medicines in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

- Daratumumab + Bortezomib + Dexamethasone [DVd]
- Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]
- Daratumumab + Lenalidomide + Dexamethasone [DRD]
- Daratumumab + Bortezomib + Lenalidomide + Dexamethasone [DVRd]
- Daratumumab (monotherapy)
- Lenalidomide + Dexamethasone [Rd]
- Lenalidomide (maintenance monotherapy)
- Belantamab mafodotin (monotherapy)
- Belantamab mafodotin + Bortezomib + Dexamethasone [BVd]
- Belantamab mafodotin + Pomalidomide + Dexamethasone [BPd]
- Isatuximab + Bortezomib + Lenalidomide + Dexamethasone [IsaVRd]
- Isatuximab + Pomalidomide + Dexamethasone [IsaPd]

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Multiple Myeloma treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
2.1 Daratumumab + Bortezomib + Dexamethasone [DVd]	26
2.2 Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]	≤5
2.3 Daratumumab + Lenalidomide + Dexamethasone [DRD]	51
2.4 Daratumumab + Bortezomib + Lenalidomide + Dexamethasone [DVRd]	10
2.5 Daratumumab (monotherapy)	16
2.6 Lenalidomide + Dexamethasone [Rd]	59
2.7 Lenalidomide (maintenance monotherapy)	57
2.8 Belantamab mafodotin (monotherapy)	Nil
2.9 Belantamab mafodotin + Bortezomib + Dexamethasone [BVd]	Nil
2.10 Belantamab mafodotin + Pomalidomide + Dexamethasone [BPd]	Nil
2.11 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone [IsaVRd]	Nil
2.12 Isatuximab + Pomalidomide + Dexamethasone [IsaPd]	9

Question:

3. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Acalabrutinib (Calquence)  
 Ibrutinib (Imbruvica)  
 Pirtobrutinib (Jaypirca)  
 Venetoclax (Venclyxto)  
 Zanubrutinib (Brukinsa)  
 Rituximab  
 Obinutuzumab (Gazyvaro)

Answer:

<b>Patient treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
3.1 Acalabrutinib (Calquence)	21
3.2 Ibrutinib (Imbruvica)	27

<b>Patient treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
3.3 Pirtobrutinib (Jaypirca)	Nil
3.4 Venetoclax (Venclyxto)	39
3.5 Zanubrutinib (Brukinsa)	30
3.6 Rituximab	151
3.7 Obinutuzumab (Gazyvaro)	14

Question:

4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Acalabrutinib (Calquence)  
 Ibrutinib (Imbruvica)  
 Pirtobrutinib (Jaypirca)  
 Venetoclax (Venclyxto)  
 Zanubrutinib (Brukinsa)  
 Obinutuzumab (Gazyvaro)  
 Rituximab

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Chronic Lymphocytic Leukaemia or Small B-Cell Lymphoma treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
4.1 Acalabrutinib (Calquence)	21
4.2 Ibrutinib (Imbruvica)	18
4.3 Pirtobrutinib (Jaypirca)	Nil
4.4 Venetoclax (Venclyxto)	29
4.5 Zanubrutinib (Brukinsa)	6
4.6 Obinutuzumab (Gazyvaro)	10
4.7 Rituximab	≤5

Question:

5. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Ibrutinib + Venetoclax  
 Obinutuzumab + Venetoclax  
 Ibrutinib monotherapy / maintenance  
 Venetoclax monotherapy  
 Venetoclax + Rituximab  
 Rituximab monotherapy  
 Rituximab + Fludarabine + Cyclophosphamide  
 Rituximab + R-CHOP  
 Rituximab + Bendamustine  
 Rituximab + Chlorambucil  
 Obinutuzumab + Chlorambucil

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Chronic Lymphocytic Leukaemia or Small B-Cell Lymphoma treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
5.1 Ibrutinib + Venetoclax	Nil
5.2 Obinutuzumab + Venetoclax	10
5.3 Ibrutinib monotherapy / maintenance	18
5.4 Venetoclax monotherapy	23
5.5 Venetoclax + Rituximab	≤5
5.6 Rituximab monotherapy	≤5
5.7 Rituximab + Fludarabine + Cyclophosphamide	Nil
5.8 Rituximab + R-CHOP	Nil
5.9 Rituximab + Bendamustine	Nil
5.10 Rituximab + Chlorambucil	Nil
5.11 Obinutuzumab + Chlorambucil	Nil

Question:

6. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Acalabrutinib  
Ibrutinib  
Zanubrutinib  
Ibrutinib + R-CHOP / R-DHAP  
Pirtobrutinib

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Mantle Cell Lymphoma treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
6.1 Acalabrutinib	Nil
6.2 Ibrutinib	≤5
6.3 Zanubrutinib	≤5
6.4 Ibrutinib + R-CHOP / R-DHAP	Nil
6.5 Pirtobrutinib	Nil

Question:

7. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Azacitidine  
Cytarabine  
Venetoclax (Venclyxto)

Answer:

<b>Acute Myeloid Leukaemia treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
7.1 Azacitidine	19
7.2 Cytarabine	7
7.3 Venetoclax (Venclyxto)	10

## Question:

8. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Venetoclax + Azacitidine (with or without posaconazole)  
 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)

## Answer:

<b>Acute Myeloid Leukaemia treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
8.1 Venetoclax + Azacitidine (with or without posaconazole)	10
8.2 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)	Nil

## Question:

9. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available?

Fedratinib (Inrebic)  
 Momelotinib (Ommjara)  
 Ruxolitinib (Jakavi)  
 Hydroxycarbamide

## Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Patient treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
9.1 Fedratinib (Inrebic)	≤5
9.2 Momelotinib (Ommjara)	8
9.3 Ruxolitinib (Jakavi)	40
9.4 Hydroxycarbamide	116

## Question:

10. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months

between the start of October 2025 and end of December 2025, or latest 3-month period available?

Ruxolitinib (Jakavi)  
 Hydroxycarbamide

Answer:

I have not released numbers of 5 or fewer in the table below, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

<b>Myelofibrosis treatment, October – December 2025, NHS Lothian</b>	
<b>Name of medicine</b>	<b>Number of patients treated</b>
10.1 Ruxolitinib (Jakavi)	15
10.2 Hydroxycarbamide	≤5

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director of Nursing Midwifery and AHPs**  
 Cc: Chief Executive